Aggregated China Business Blogs



AIDA Pharmaceuticals Announces Favorable Clinical Trial Findings

Aggregated Source: Seeking Alpha China stocks
October 24, 2007|

Aida Pharmaceuticals, Inc. (AIDA.OB) yesterday announced an update on its testing of Rh-Apo2L, currently in Phase IIA of testing through China's State Food and Drug Administration [SFDA].

Original URL: Click here to visit original article
Copyright Seeking Alpha China stocks

Print This Post Print This Post | Email This Page Email This Page
No Ratings Yet
Loading ... Loading ...

Related Info:
  • Immtech Conducts Pneumonia Drug Trials on the Fast Track
  • SL Pharma Wins SFDA Approval for New Drug and a Clinical Trial
  • Tongjitang's Osteoperosis Drug Likely to Win FDA Approval
  • China Pushes Ahead of India in Clinical Trials
  • Genesis Pharmaceuticals Announces China SFDA Approval For Radix Isatidis Dispersible Tablets

    • No Comments Yet »

    Your comment

    The following HTML tags are permitted:
    <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

    RSS RSS Feed for Comments on this Post |